News
ALGS
0.6100
-0.49%
-0.0030
Weekly Report: what happened at ALGS last week (0520-0524)?
Weekly Report · 3d ago
Aligos Therapeutics Completes Enrollment In The ALG-055009 Phase 2a HERALD Study For The Treatment Of MASH
Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator for the study. Aligos Therapeutics has completed enrollment in the ALG-055009 Phase 2a HERALD study for metabolic dysfunction-associated steatohepatitis.
Benzinga · 05/21 12:20
ALIGOS THERAPEUTICS INC - TOPLINE DATA NOW PROJECTED IN EARLY Q4 2024
Reuters · 05/21 12:00
ALIGOS THERAPEUTICS ANNOUNCES THE COMPLETION OF ENROLLMENT IN THE ALG-055009 PHASE 2A HERALD STUDY FOR THE TREATMENT OF MASH
Reuters · 05/21 12:00
Weekly Report: what happened at ALGS last week (0513-0517)?
Weekly Report · 05/20 09:17
Piper Sandler Keeps Their Buy Rating on Aligos Therapeutics (ALGS)
TipRanks · 05/17 10:27
After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)
NASDAQ · 05/16 13:35
Aligos Therapeutics Announces Chief Medical Officer Resignation
TipRanks · 05/15 21:12
Weekly Report: what happened at ALGS last week (0506-0510)?
Weekly Report · 05/13 09:18
Hold Rating on Aligos Therapeutics Amidst Clinical Trials and Financial Stability
TipRanks · 05/10 05:15
Aligos Therapeutics reports Q1 results
Aligos Therapeutics reports Q1 results. Revenue from collaborations and customers of $986M (-63.8% Y/Y). Cash, cash equivalents and investments totaled $112.7M as of March 31. Aligos raised $92.1 million in private placement financing in October 2023.
Seeking Alpha · 05/08 14:42
Piper Sandler Sticks to Their Buy Rating for Aligos Therapeutics (ALGS)
TipRanks · 05/08 11:10
ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024
Aligos Therapeutics reported earnings per share of -22 cents for the first quarter of 2024. The company reported revenue of $986,000. This was below the analyst estimate for EPS of -19 cents. Aligos reported results for first quarter 2024.
Investorplace · 05/08 01:56
Aligos Therapeutics Q1 2024 GAAP EPS $(0.22) Misses $(0.19) Estimate, Sales $986.000K Down From $2.723M YoY
Aligos Therapeutics reported quarterly losses of $0.22 per share. The company missed the analyst consensus estimate by 15.79%. The company reported $986.000 thousand in sales for the quarter, down 63.79 percent from the same period last year.
Benzinga · 05/07 21:07
ALIGOS THERAPEUTICS INC: CONTINUE TO BELIEVE OUR CASH BALANCE PROVIDES SUFFICIENT CASH TO FUND PLANNED OPERATIONS THROUGH END OF 2025
Reuters · 05/07 20:05
Press Release: Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
Aligos Therapeutics reports recent business progress and financial results for the first quarter 2024. The company is focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. Aligos recently began dosing in the Phase 2a HERALD study of its hepatitis B virus drug candidate.
Dow Jones · 05/07 20:05
Press Release: Aligos Therapeutics Reports Recent -2-
General and administrative expenses, net of interest and other costs. Total operating expenses are less than $100 million. The company has a net loss of more than $50 million for the year. The company expects to be in the black for the full year of 2024. The Company has a cash balance of $1.2 billion.
Dow Jones · 05/07 20:05
Weekly Report: what happened at ALGS last week (0429-0503)?
Weekly Report · 05/06 09:19
Aligos Therapeutics, Inc.: Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Press release · 04/29 23:14
Weekly Report: what happened at ALGS last week (0422-0426)?
Weekly Report · 04/29 09:20
More
Webull provides a variety of real-time ALGS stock news. You can receive the latest news about Aligos Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ALGS
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases. The Company discovers and develops therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and viruses with high unmet medical need, such as chronic hepatitis B (CHB) and coronaviruses. Its advanced drug candidate for MASH is ALG-055009, a small molecule thyroid hormone receptor beta (THR-ß) agonist. It is also progressing oligonucleotide projects for MASH. It is developing a portfolio of differentiated CHB drug candidates, including a small molecule Capsid Assembly Modulator that results in the production of empty viral capsids (CAM-E) and small molecule inhibitors of the Programmed Cell Death Ligand 1 (PD-1/PD-L1) interaction. Its third area of focus is to develop drug candidates with pan-coronavirus antiviral activity. Its pipeline includes ALG-055009, ALG-000184, ALG-125755, and ALG-097558.